ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.

Clinical cancer research : an official journal of the American Association for Cancer Research2013Huang HY, Wu WR, Wang YH, et al.

Scholarly article — Journal Article / Research Support, Non-U.S. Gov't

Study designOther literature / records

SubjectHuman & animal

Record checks

Study design: Other literature / records
Subject: Human & animal
Publication year: 2013
Source: doi.org
Abstract display: Not reproduced here
Publication status: Active
Status checked: 17 Aug 2026
Collected: 13 Aug 2026
Freshness: Current
Review stage: Automated
Record status: Published

How to read this record →

Abstract

The abstract is not reproduced here. Please consult the original source.

MeSH

AdultAgedAmino-Acid N-AcetyltransferaseAnimalsArgininosuccinate SynthaseCell Line, TumorCell MovementCell ProliferationCell SurvivalCluster AnalysisDNA MethylationFemaleFibrosarcomaG1 Phase Cell Cycle CheckpointsGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesGenes, Tumor SuppressorHumansHydrolasesLeiomyosarcomaMaleMiceMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingNeovascularization, PathologicPhenotypePolyethylene GlycolsPrognosisXenograft Model Antitumor Assays

DOI 10.1158/1078-0432.ccr-12-2641

PMID 23549872

View source →